Download Free Medical Malignant Ovarian Tumours PowerPoint Presentation

Malignant Ovarian Tumours PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Malignant Ovarian Tumours” by Ass. Prof. Dr Ban Hadi Hameed.

This medical PowerPoint presentation is about malignant ovarian tumors, tumors that arise from the cells of the ovary and have the potential to spread to other parts of the body. These tumors can be classified into several types based on their cell type and how they appear under the microscope. The three main types of malignant ovarian tumors are Epithelial ovarian tumors, Germ cell ovarian tumors, and Sex cord-stromal ovarian tumors.

Tags : Malignant Ovarian Tumours, Epithelial ovarian tumors, Germ cell ovarian tumors, Sex cord-stromal ovarian tumors, Gynaecology, Gynaecology PowerPoint presentation, Gynecologic Oncology, Gynecologic Oncology PowerPoint presentation

Published on : May 29, 2023 | Views : 834 | Downloads : 0

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Malignant Ovarian tumours: Ass. Prof. Dr Ban Hadi Hameed Mustansiriyah university 2021
Slide 2-

LEARNING OBJECTIVES: Fifth year students should be able to: Describe the types of malignant ovarian tumours Summarize the important points in history and examination to reach the diagnosis Interpret ultrasound and investigations results Predict the management option for different case scenarios according to their presentation
Slide 3-

Ovarian cancer is the second most common gynaecological malignancy and the major cause of death from gynaecological cancer in the UK. When detected in its early stages, ovarian cancer has an excellent prognosis. The dismal overall survival rates from ovarian cancer reflect the advanced stage at which most women present.
Slide 4-

Incidence the mean age of presentation is 64 years. Ovarian cancer is more prevalent in higher income nations. white women have the highest incidence, whereas Asian women have a lower incidence. Ovarian cancer is rare in young women and only 3% of ovarian cancers occur in women under 35 years. There is a significant genetic aspect to ovarian cancer. It should be noted that less than 20% of adnexal masses in premenopausal women are found to be malignant; in postmenopausal women this increases to around 50%.
Slide 5-

Histological Classification of ovarian cancer: Primary and secondary tumours 1. Epithelial ovarian tumours (80%) Serous, Endometrioid, Clear cell, Mucinous 2. Sex cord stromal tumours (10%) Granulosa cell, Sertoli–Leydig, Gynandroblastoma 3. Germ cell tumours (10%) Dysgerminoma, Endodermal sinus (yolk sac), Teratoma Choriocarcinoma 4. Metastatic (including Krukenberg tumours)
Slide 6-

Epithelial tumours of the ovary: The majority of ovarian neoplasia both benign &malignant arises from the ovarian surface epithelium. Endocervical= mucinous cyst adenocarcinoma. Endometrial= endometrioid. Tubal = serous cyst adenocarcinoma. Uroepithelial= Brenner tumour
Slide 7-

Borderline ovarian tumours (BOTs). These tumours are well differentiated, with some features of malignancy (nuclear pleomorphism, cellular atypia) but do not invade the basement membrane. BOTs spread to other abdominopelvic structures (peritoneum, omentum) but do not often recur following initial surgery
Slide 8-

Risk factors for ovarian cancer: Increased risk : Nulliparity, Intrauterine device, Endometriosis, Smoking, Obesity, Early menarche, Late menopause, White race, Increasing age, Family history, American and Europe residence. Decreased risk: Multiparity, Combined oral contraceptive pills, Tubal ligation, Salpingectomy, Hysterrectomy. The ‘incessant ovulation’ theory
Slide 9-

Genetic factors in ovarian cancer: It is estimated that at least 10–15% of women with epithelial ovarian cancer have a hereditary predisposition. Women with mutations in BRCA1, BRCA2 and Lynch syndrome have an increased lifetime risk of epithelial ovarian cancer. The most common hereditary cancer is the breast ovarian cancer syndrome (BRCA), accounting for 90% of the hereditary cancers. This syndrome is due to a mutation of tumour suppressor genes BRCA1 (80%) and BRCA2 (15%). Lynch syndrome is hereditary non-polyposis colorectal cancer (HNPCC) and is associated with endometrial cancer and a 10% lifetime risk of ovarian cancer.
Slide 10-

Prevention of ovarian cancer: Women who test positive for a BRCA mutation are offered risk-reducing measures: 1. Prophylactic bilateral salpingo-oophorectomy BSO when they have completed their families. 2. Bilateral salpingectomy with delayed oophorectomy in the 30s and early 40s 3. Tubal ligation (sterilization) and 4. Hysterectomy with ovarian conservation. 5. Chemoprevention using the combined oral contraceptive pill (COCP)
Slide 11-

Screening: transvaginal ultrasound scan (TVUSS) and CA125 measurement has not been shown to improve survival in women with a familial predisposition to ovarian cancer.
Slide 12-

Diagnosis: Age, Symptoms and risk factors Age: the mean age of presentation is 64 years Symptoms: Most women with ovarian cancer have non-specific and often vague symptoms is the main reason that patients with ovarian cancer present with late stage disease (66% present with stage 3 disease or greater), and this has a dramatic effect on survival.
Slide 13-

The most common symptoms are: • Increased abdominal girth/bloating. • Persistent pelvic and abdominal pain. • Difficulty eating and feeling full quickly. Other symptoms such as change in bowel habit, urinary symptoms, back ache, irregular bleeding and fatigue occur frequently Risk factors: for ovarian cancer
Slide 14-

Examination: General: General health, BMI, pallor, jaundice, Lymph nodes examination neck and groin, Leg oedema in cases of tumours due to pressure effect or invasion of pelvic vessels Breast, neck and chest examination. Pleural effusion goes with malignancy Abdominal examination may reveal a fixed, hard mass arising from the pelvis so that we can not palpate below it, ascites demonstrated by shifting dullness and/or a fluid thrill Pelvic examination: Early-stage ovarian cancer is difficult to diagnose due to the position of the ovary, but an adnexal mass may be palpable in a slim woman. Features of malignancy are fixed, hard, bilateral adnexal masses invaded other organs.
Slide 15-

Investigations 1.Ultrasound: Consistency, the presence of solid elements, as papillary projections Bilateral tumour, The presence of ascites Extra-ovarian disease, including peritoneal thickening and omental deposits Increased vascularity by color Doppler. Large mass > 10 cm with loculation
Slide 16-

Unilocular versus multilocular
Slide 17-

ppt slide no 17 content not found
Slide 18-

Mucinous cyst adenoma
Slide 19-

Malignant tumour
Slide 20-

Benign versus malignant
Slide 21-

Border line ovarian tumour
Slide 22-

Dermoid cyst
Slide 23-

2.Tumour markers Tumour markers: CA125 is a non-specific tumour marker that is elevated in over 80% of epithelial ovarian cancers
Slide 24-

The Risk of Malignancy Index (RMI) is calculated from menopausal status, pelvic ultrasound features and CA125 level to triage pelvic masses into those at low, intermediate and high RMI = U * M *CA125. According to this patient are classified into: Low risk : score < 25. Moderate: score 25 -250. High : score > 250.
Slide 25-

ppt slide no 25 content not found
Slide 26-

3.Pelvic pathology at intermediate or high risk of malignancy is further imaged using computed tomography (CT) and/or magnetic resonance imaging (MRI) scans.
Slide 27-

4.Other investigations required for preoperative work-up include chest X-ray,electrocardiography (ECG), full blood count, urea and electrolytes, and liver function tests.
Slide 28-

5.If the patient presents with gross ascites or pleural effusion, paracentesis or pleural aspiration may be required for symptom relief and/or diagnosis. A sample of the fluid removed is sent for cytological assessment.
Slide 29-

6.If the diagnosis is uncertain or if primary chemotherapy is being considered (for advanced disease, or in patients not fit to undergo surgery), a biopsy is needed before treatment can be given. This is performed laparoscopically or radiologically (ultrasound or CT-guided biopsy). Usually the omentum is a good site for biopsy.
Slide 30-

Staging Ovarian cancer staging is based on clinic-pathological assessment Overall, 25% of patients present with stage 1 disease, 10% stage 2, 50% stage 3 and 15% stage 4 disease. Stage I: Ovarian cancer Stage II: Ovarian cancer has spread to other parts of the pelvic region Stage III: Ovarian cancer has spread to the abdomen Stage IV: Ovarian cancer has spread beyond the abdomen, like the lungs and liver
Slide 31-

Metastatic spread: 2/3 of patient with ovarian cancer present with disease that has spread beyond the pelvis. Women with early ovarian cancer (stages 1 and 2) have up to 20% metastatic spread to lymph nodes and this rises to 60% in advanced disease 1. Direct spread 2. Peritoneal fluid (large& small bowel, parietal peritoneal surface, liver) 3. Lymphatic spread (pelvic& para-aortic lymph nodes, cervical nodes) 4. Haematogenous spread: usually occurs late (liver, lung, bone, brain).
Slide 32-

Treatment Surgery: Provided the patient is fit to undergo anaesthesia, surgery remains necessary for: *diagnosis *staging *treatment of epithelial ovarian cancer.
Slide 33-

If the patient is at high risk of ovarian cancer, the surgery should only be performed by a gynaecological oncologist, as this has been shown to improve outcomes. The objective of surgery is to stage accurately the disease and remove all visible tumour. The aim of surgery is complete or optimal cytoreduction (where <1 cm of residual macroscopic disease is left behind).
Slide 34-

Principle of surgical treatment: A vertical incision is required to gain access to all areas of the abdomen. Ascites or peritoneal washings are sampled A total abdominal hysterectomy and BSO performed along with an omentectomy. Further debulking may be required, possibly including resection of bowel, peritoneal stripping or splenectomy in order to remove all tumour. Lymph node resection is important, particularly in early-stage disease Restaging can be offered after treatment and this may be carried out laparoscopically.
Slide 35-

Occasionally, young patients who are found to have an early-stage epithelial ovarian cancer wish to have conservative, fertility sparing surgery. In these cases, unilateral salpingo–oophorectomy, omentectomy, peritoneal biopsies and pelvic/para-aortic node dissection can be performed with endometrial sampling to exclude a synchronous tumour.
Slide 36-

Chemotherapy: Chemotherapy can be given as primary treatment, as an adjunct following surgery or for relapse of disease
Slide 37-

Primary chemotherapy may be offered if a patient is unfit or unwilling to have surgery, or if preoperative assessment indicates that complete debulking is unlikely to be achievable,. If the patient responds to the chemotherapy, interval surgery can be carried out after three cycles.
Slide 38-

If the cancer has been properly staged as stage 1a or b, and is histologically low grade (well or moderately differentiated), chemotherapy may be withheld. The role of chemotherapy in stage 1c disease is uncertain, but in practice most patients will be offered postoperative chemotherapy as with all other stages of epithelial ovarian cancer.
Slide 39-

Surgery combined with platinum-based chemotherapy is the mainstay of treatment for advanced ovarian cancer. First-line treatment is usually a combination of a platinum compound with paclitaxel. Most regimes are given on an outpatient basis, 3 weeks apart for six cycles.
Slide 40-

Prognosis The survival figures depend on stage at presentation, volume of disease following surgery and the histological grade of tumour and age at resentation The overall 5-year survival from ovarian cancer is 46% in the UK Survival is stage dependent: overall 5-year survival for stage 1 disease is over 90% compared to 30% for stage 3 disease.
Slide 41-

Sex cord stromal tumours: These tumours account for approximately 10% per cent of ovarian tumours, but almost 90% cent of all functional (i.e. hormone-producing) tumours. Generally, they are tumours of low malignant potential with a good long-term prognosis. Some morbidity may arise from the oestrogen (granulosa cell) or androgen production (Seroli–Leydig cell) characteristic of these tumours, resulting in precocious puberty, abnormal menstrual bleeding and an increased risk of endometrial cancer.
Slide 42-

Sex cord stromal tumours: The peak incidence is around the age of the menopause Sertoli–Leydig cell tumours produce androgens in over 50% of cases. Patients present with a pelvic mass and signs of virilization. Common symptoms are amenorrhoea, deep voice and hirsutism Occasionally, this group of tumours produce oestrogen and rarely renin, causing hypertension. Granulosa cell tumours produce inhibin, which can be used for follow-up Treatment Surgery is the mainstay of treatment as there is no effective chemotherapy regime.
Slide 43-

Germ cell tumours Malignant germ cell tumours occur mainly in young women and account for approximately 10% of ovarian tumours. They are derived from primordial germ cells within the ovary and because of this may contain any cell type.
Slide 44-

Germ cell tumours Dysgerminomas account for 50% of all germ cell tumours. They are bilateral in 20% of cases and occasionally secrete human chorionic gonadotrophin (hCG). Endodermal sinus yolk sac tumours are the second most common germ cell tumours They are rarely bilateral and secrete α-fetoprotein (AFP).
Slide 45-

Germ cell tumours Immature teratomas are malignant germ cell tumours and about 1% of all teratomas. They are classified as mature or immature depending on the grading of neural tissue present. About one-third of teratomas secrete AFP. Non-gestational choriocarcinomas are very rare, usually presenting in young girls with irregular bleeding and very high levels of hCG.
Slide 46-

Treatment As most women presenting with malignant germ cell tumours are of reproductive age, fertility-sparing surgery is the mainstay with chemotherapy if the disease reaches outside the ovary. The most common regime used is a combination of bleomycin, etoposide and cisplatin (BEP). This regime preserves fertility
Slide 47-

End of lecture questions?
Slide 48-

Question: Mrs L is a 62-year-old woman who presents to the gynaecology clinic with non-specific abdominal pain, a change in bowel habit and bloating. Her GP arranged a pelvic ultrasound scan, which found bilateral complex solid/cystic pelvic masses, large volume ascites and omental caking. A What is the most likely diagnosis? B What are the key points in the examination and investigation? Mrs L is found to have stage 3 high-grade serous ovarian cancer. C How would you manage her?
Slide 49-

Answer: The scan report shows features suggestive of advanced ovarian cancer (solid/cystic pelvic masses, ascites and extraovarian disease). B Pelvic examination may reveal hard, fixed pelvic masses and free fluid in the abdomen (ascites) is demonstrated by shifting dullness and/or a fluid thrill. Investigations include serum CA125 levels. If the tumour secretes CA125, this can be used as a non-invasive test to monitor treatment response and subsequently screen for recurrent disease. CT scan, paracentesis, biopsy
Slide 50-

Treatment: If Mrs L is fit for surgery and preoperative investigations suggest that complete tumour debulking is achievable, upfront surgery followed by six cycles of adjuvant carboplatin and paclitaxel chemotherapy is generally preferred. Surgery involves a midline laparotomy, total hysterectomy (removal of uterus and cervix) and BOS (removal of both Fallopian tubes and ovaries), omentectomy, pelvic lymphadenectomy and debulking of any extraovarian tumour deposits. Sometimes surgery is avoided in the primary setting because the disease is not completely resectable, and in this scenario, three cycles of neoadjuvant chemotherapy are given and a restaging CT scan performed to decide whether surgery now is likely to remove all tumour deposits. If surgery takes place, the patient receives a further three cycles of chemotherapy afterwards.
Slide 51-

Match the suitable answers: For each description below, choose the SINGLE most appropriate answer from the list of options A High-grade pelvic serous carcinoma. B Mucinous BOT. C Endometrioid ovarian cancer. D Immature teratoma. E Dysgerminoma. F Granulosa cell tumour. G Choriocarcinoma of the ovary. H Sertoli–Leydig ovarian tumour. I Dermoid cyst. J Krukenberg tumour. 1 Associated with STIC lesions in the Fallopian tube. 2 Commonly associated with BRCA mutation carrier status. 3 May present with amenorrhoea, deep voice, hirsutism and acne. 4 May provoke precocious puberty in young girls. 5 Associated with endometriosis. 6 Secretes inhibin. 7 Associated with appendiceal tumours and pseudomyxoma peritoneii. 8 May contain hair, teeth, bone, cartilage and sebum. 9 Metastatic ovarian tumour from colorectal or breast primary.
Slide 52-

ANSWERS 1A The term high-grade pelvic serous carcinoma has been coined to incorporate all high-grade serous tumours arising from the ovary, Fallopian tube and/or peritoneum. There may be tubal precursors, which are called serous tubal intraepithelial carcinoma (STIC) lesions, and they are characterized by mutations in p53 in secretory cells of the distal Fallopian tube. 2A As many as 30% of high-grade pelvic serous cancers have BRCA mutations. 3H Sertoli—Leydig cell tumours produce androgens in over 50% of cases. Patients present with a pelvic mass and signs of virilization. 4F Granulosa cell tumours frequently secrete oestrogen. Part of the work-up of girls presenting in this way would be to exclude oestrogen-secreting tumours. Granulosa cell tumours may also present as a large pelvic mass or with pain due to torsion/haemorrhage.
Slide 53-

5C Endometriosis-associated ovarian cancers are usually of endometrioid or clear cell histological subtype. 6F Granulosa cell tumours produce inhibin, which can be used for follow-up surveillance; levels often rise prior to clinical detection of recurrence. 7B Mucinous BOTs may actually arise from the appendiceal carcinomas of low malignant potential and can be associated with pseudomyxoma peritoneii. 8I Dermoids are classically associated with tissue such as hair and teeth, and a TVUSS can be diagnostic. They are usually benign. 9J The ovary is also a common site for metastatic spread; Krukenberg tumours are ovarian metastases associated with primary cancers of the colon, stomach and breast.
Slide 54-

SBA QUESTIONS A 34-year-old woman attends the gynaecology department because she has tested positive for a BRCA1 mutation. She wishes to lower her risk of ovarian cancer as much as possible. She is otherwise fit and well with no past medical history of note. Her cervical smears are up to date and normal. What surgery would you recommend? Choose the single best answer. A Bilateral oophorectomy. B Bilateral salpingectomy with delayed oophorectomy. C BSO. D Subtotal hysterectomy and BSO. E Total hysterectomy and BSO.
Slide 55-

ANSWER C Unless there are convincing reasons for hysterectomy as well, removing both Fallopian tubes and ovaries is the best way to reduce the risk of ovarian cancer (90%) and premenopausal breast cancer (50%). The downside is the surgical menopause that will ensue, but this can be effectively managed with continuous combined hormone replacement therapy (HRT). There is little evidence to suggest that this is harmful to cancer risk if there is no personal history of breast cancer (in which case, all forms of HRT are avoided).
Slide 56-

Question 2 SBA 2 A 58-year-old woman presents with a large pelviabdominal mass extending to the level of the xiphisternum. It has a heterogeneous appearance on scan with solid and cystic components. The rest of the pelvis and abdomen appears normal and there is no free fluid. The CA125 level is 430 units. She is asymptomatic. How would you manage this patient? Choose the single best answer. A Laparoscopic ovarian cystectomy. B Laparotomy, total abdominal hysterectomy, BSO, pelvic and para-aortic lymph node sampling, omentectomy and debulking of tumour deposits. C Repeat scan and CA125 in 3 months to check for interval change. D Six cycles of neoadjuvant carboplatin and paclitaxel-based chemotherapy followed by restaging CT scan at 3 months. E Ultrasound-guided transcutaneous aspiration of ovarian cyst fluid and cytological assessment.
Slide 57-

ANSWER B This patient has a high risk of malignancy index (RMI) and therefore should undergo a full staging laparotomy and complete debulking. If the ovarian mass is the only abnormal finding at laparotomy, intraoperative frozen sections can be used to direct further surgical effort, since pelvic and para-aortic lymphadenectomy is not required if the cyst is benign. Aspiration of the cyst is avoided when malignant
Slide 58-

References: Gynecology by ten teachers Dewhurt's textbook of Obstetrics and gynecologyFurther reading Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ (eds) (2002). Handbook of Gynecologic Oncology.